Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Related Posts

Association of Eicosanoids and Eicosanoid-Related Metabolites With Obesity and Cardiometabolic Traits

Chitsazan M, Parekh JK, Grundmann AL, Lau ES, Alotaibi M, Yu B, Rebholz CM, Selvin E, Allen NB, Allison MA, Jain M, Cheng S, Ho[...]

Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Podany EL, Foffano L, Gerratana L, Medford AJ, Heater NK, Nicolò E, Tapiavala S, Pontolillo L, Putur A, Jaber DA, Clifton K, Katakam N, Addison[...]

Epigenetic Clocks of Biological Aging and Cognitively Healthy Longevity: The Women’s Health Initiative Memory Study

LaCroix AZ, Zhang B, Nguyen S, Resnick SM, Ferrucci L, Horvath S, Lu AT, Espeland MA, Rapp SR, Beckman K, Nievergelt C, Maihofer AX, McEvoy[...]